Tempest Therapeutics Inc Cash Flow Conversion Efficiency
Tempest Therapeutics Inc cash flow conversion efficiency. Based on the latest financial reports, Tempest Therapeutics Inc (TPST) has a cash flow conversion efficiency ratio of 2.550x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.78 Million) by net assets ($-1.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Tempest Therapeutics Inc (2012–2025)
Cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2025. This chart illustrates how Tempest Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Tempest Therapeutics Inc for real-time trading data and today's change.
Tempest Therapeutics Inc Cash Flow Conversion Ratio Explained
Tempest Therapeutics Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Tempest Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tempest Therapeutics Inc ranked by their cash flow conversion efficiency. Also see Tempest Therapeutics Inc market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ENERGY S.P.A.
F:S2I
|
N/A |
|
International Graphite Ltd
AU:IG6
|
-0.184x |
|
Oxford BioMedica PLC
LSE:OXB
|
0.072x |
|
Augros Cosmetic Packaging SA
PA:AUGR
|
-0.287x |
|
2020 Bulkers Ltd.
F:0FF
|
0.104x |
|
BioLine RX Ltd
TA:BLRX
|
-0.193x |
|
E Media Holdings Ltd
JSE:EMH
|
0.047x |
|
ZHONGLIANG HLDG HD-01
F:3ZH
|
N/A |
Annual Cash Flow Conversion Efficiency for Tempest Therapeutics Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Tempest Therapeutics Inc from 2012 to 2025. Review Tempest Therapeutics Inc (TPST) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.67 Million | $-26.82 Million | -4.022x | -132.93% |
| 2024-12-31 | $19.13 Million | $-33.03 Million | -1.727x | -68.96% |
| 2023-12-31 | $26.77 Million | $-27.36 Million | -1.022x | +40.43% |
| 2022-12-31 | $18.11 Million | $-31.07 Million | -1.716x | -138.72% |
| 2021-12-31 | $36.12 Million | $-25.96 Million | -0.719x | -359.98% |
| 2020-12-31 | $-68.79 Million | $-19.02 Million | 0.276x | +140.15% |
| 2019-12-31 | $59.87 Million | $-41.22 Million | -0.689x | -112.90% |
| 2018-12-31 | $73.12 Million | $-23.65 Million | -0.323x | +76.18% |
| 2017-12-31 | $14.98 Million | $-20.34 Million | -1.358x | -137.97% |
| 2016-12-31 | $108.22 Million | $-61.73 Million | -0.570x | -43.90% |
| 2015-12-31 | $126.85 Million | $-50.29 Million | -0.396x | +28.30% |
| 2014-12-31 | $55.33 Million | $-30.59 Million | -0.553x | -27.42% |
| 2013-12-31 | $41.70 Million | $-18.09 Million | -0.434x | -19.49% |
| 2012-12-31 | $30.72 Million | $-11.16 Million | -0.363x | -- |
About Tempest Therapeutics Inc
Tempest Therapeutics, Inc., a clinical-stage biotechnology company, develops small molecule therapeutics to treat cancer. Its lead product candidates include Amezalpat, an oral small molecule selective antagonist of peroxisome proliferator-activated receptor alpha for the treatment of first-line unresectable or metastatic hepatocellular carcinoma that completed Phase 2 clinical trial; and TPST-14… Read more